Stock BLISSGVS BLISS GVS PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Bliss GVS Pharma Limited Share Price NSE India S.E.

Equities

BLISSGVS

INE416D01022

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 09:30:15 03/05/2024 am IST 		5-day change 1st Jan Change
119.2 INR -7.92% Intraday chart for Bliss GVS Pharma Limited +3.46% -5.33%
02/05 Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 CI
23/01 Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Financials

Sales 2022 7.47B 89.67M Sales 2023 7.52B 90.17M Capitalization 7.42B 89.03M
Net income 2022 150M 1.8M Net income 2023 709M 8.51M EV / Sales 2022 1.03 x
Net cash position 2022 256M 3.07M Net Debt 2023 335M 4.02M EV / Sales 2023 1.03 x
P/E ratio 2022
53.8 x
P/E ratio 2023
10.6 x
Employees 763
Yield 2022
0.65%
Yield 2023
0.7%
Free-Float 34.66%
More Fundamentals * Assessed data

Chart Bliss GVS Pharma Limited

Dynamic Chart

Latest news about Bliss GVS Pharma Limited

Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Assistant Commission of State Tax Maharashtra, Mumbai Initiates Search At Certain Premises of Bliss GVS Pharma Limited CI
Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Gets Establishment Inspection Report from US FDA for Palghar, India Unit MT
Bliss Gvs Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable MT
Bliss GVS Pharma Gets Three Observations from US FDA's Plant Inspection in Maharashtra, India MT
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bliss GVS Pharma Names New CFO MT
More news

Analyst Recommendations on Bliss GVS Pharma Limited

Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable MT
Infomerics Raises Rating on Bliss GVS Pharma's Long-Term Bank Financing to BBB; Outlook Lowered to Stable MT
More recommendations

Press releases Bliss GVS Pharma Limited

Bliss GVS Pharma Presents Gh?150,000 Anti-Malaria Drugs to Hospitals AQ
More press releases

Quotes and Performance

1 day-8.81%
1 week+3.46%
Current month+4.56%
1 month+1.68%
3 months+4.19%
6 months+40.31%
Current year-5.33%
More quotes

Highs and lows

1 week
113.55
Extreme 113.55
131.00
1 month
108.00
Extreme 108
131.00
Current year
100.20
Extreme 100.2
142.40
1 year
70.85
Extreme 70.85
149.60
3 years
66.10
Extreme 66.1
149.60
5 years
66.10
Extreme 66.1
221.00
10 years
38.95
Extreme 38.95
221.00
More quotes

Managers and Directors - Bliss GVS Pharma Limited

Managers TitleAgeSince
Gagan Harsh Sharma CEO
 Chief Executive Officer 41 21/21/21
Deepak Sawant DFI
 Director of Finance/CFO 44 30/22/30
Aditi Himanshu Bhatt CMP
 Compliance Officer - 09/15/09
Members of the board TitleAgeSince
Subramanian R. Vaidya CHM
 Chairman 81 01/11/01
Vibha Gagan Sharma BRD
 Director/Board Member 40 29/08/29
Shruti Vishal Rao BRD
 Director/Board Member 39 27/06/27
More insiders

Quotes

Date Price Change Volume
03/24/03 119.2 -7.92% 809 109
02/24/02 129.4 +4.69% 1,231,953
30/24/30 123.6 -0.76% 1,356,702
29/24/29 124.6 +1.55% 640,749
26/24/26 122.6 +4.87% 1,108,202

Delayed Quote NSE India S.E., May 03, 2024 at 09:30 am IST

More quotes

Company Profile

Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Sector
Pharmaceuticals
Calendar
17/05/2024 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.97% 43.18B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.67% 22.59B
SANDOZ GROUP AG Stock Sandoz Group AG
+14.56% 14.56B
CIPLA LIMITED Stock Cipla Limited
+13.89% 13.54B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+42.80% 11.5B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.37% 6.93B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+10.21% 5.36B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BLISSGVS Stock
  4. BLISSGVS Stock